Lyse Norian Ph.D.

Faculty Member

Selected Publications

Academic Article

Year Title Altmetric
2020 Body fat indices and survival in immunotherapy-treated patients with cancerCancer.  126:3156-3157. 2020
2020 PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression 2020
2020 Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancerGynecologic Oncology.  157:765-774. 2020
2020 Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristicsInternational Journal of Cancer.  146:2784-2796. 2020
2020 Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomesImmunological Reviews.  295:203-219. 2020
2020 Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinomaPLoS ONE.  15. 2020
2020 ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastomaNeuro-Oncology.  22:333-344. 2020
2020 Inhibiting WNT ligand production for improved immune recognition in the Ovarian tumor microenvironmentCancers.  12. 2020
2020 Corrigendum to ‘Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer’ [Gynecologic Oncology 157 (2020) 765–774] (Gynecologic Oncology (2020) 157(3) (765–774), (S0090825820302262), (10.1016/j.ygyno.2020.03.010))Gynecologic Oncology2020
2020 Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer 2020
2019 Inverse association between changes in energetic cost of walking and vertical accelerations in non-metastatic breast cancer survivorsEuropean Journal of Applied Physiology.  119:2457-2464. 2019
2019 Checkpoint inhibitors in ovarian cancer: A review of preclinical dataGynecologic Oncology Reports.  29:48-54. 2019
2019 A review of the role of wnt in cancer immunomodulationCancers.  11. 2019
2019 Targeting glucose metabolism to enhance immunotherapy: Emerging evidence on intermittent fasting and calorie restriction mimeticsFrontiers in Immunology.  10. 2019
2018 The antitumor effects of entinostat in ovarian cancer require adaptive immunityCancer.  124:4657-4666. 2018
2018 Effects of diet on immune cells within the central nervous systemPhysiology and Behavior.  196:158-164. 2018
2018 Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastomaCancer Research.  78:3002-3013. 2018
2018 Reply to "phase II prospective randomized trial of weight loss prior to radical prostatectomyProstate Cancer and Prostatic Diseases.  21:293-294. 2018
2018 Ease of walking associates with greater free-living physical activity and reduced depressive symptomology in breast cancer survivors: pilot randomized trialSupportive Care in Cancer.  26:1675-1683. 2018
2017 Obesity as defined by waist circumference but not body mass index is associated with higher renal mass complexityUrologic Oncology: Seminars and Original Investigations.  35:661.e1-661.e6. 2017
2017 Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications for Cystectomy in Bladder Cancer 2017
2017 Obesity Does Not Exacerbate the Protumorigenic Systemic Environment in Sarcoma Subjects.Immunohorizons.  1:20-28. 2017
2017 Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growthOncotarget.  8:44159-44170. 2017
2017 Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancerBritish Journal of Cancer.  117:1303-1313. 2017
2016 NLRC4 suppresses melanoma tumor progression independently of inflammasome activationJournal of Clinical Investigation.  126:3917-3928. 2016
2016 Obesity alters immune and metabolic profiles: New insight from obese-resistant mice on high-fat diet 2016
2016 Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A reviewGynecologic Oncology.  143:674-683. 2016
2015 Enhancing dendritic cell-based immunotherapy with IL-2/monoclonal antibody complexes for control of established tumorsJournal of Immunology.  195:4537-4544. 2015
2015 Obesity triggers enhanced MDSC accumulation in murine renal tumors via elevated local production of CCL2PLoS ONE.  10. 2015
2015 The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in miceLeukemia.  29:233-237. 2015
2015 BKCa channel inhibitor modulates the tumorigenic ability of hormone-independent breast cancer cells via the Wnt pathway 2015
2014 A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer 2014
2014 CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma 2014
2014 Diet-induced obesity does not impact the generation and maintenance of primary memory CD8 T cellsJournal of Immunology.  193:5873-5882. 2014
2014 Effects of obesity on immune responses to renal tumorsImmunologic Research.  59:211-219. 2014
2014 Minimal changes in the systemic immune response after nephrectomy of localized renal massesUrologic Oncology: Seminars and Original Investigations.  32:589-600. 2014
2014 Tumor lysate-loaded biodegradable microparticles as cancer vaccinesExpert Review of Vaccines.  13:9-15. 2014
2012 Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growthJournal of Immunology.  189:1311-1321. 2012
2012 Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapyPLoS ONE.  7. 2012
2011 Advances in viral vector-based TRAIL gene therapy for cancerCancers.  3:603-620. 2011
2009 Synergistic induction of apoptosis in primary B-CLL cells after treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand and histone deacetylase inhibitorsJournal of Oncology2009
2009 TRAIL gene therapy: From preclinical development to clinical application 2009
2009 Tumor-Infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-Arginine metabolismCancer Research.  69:3086-3094. 2009
2008 Tumors induce regulatory dendritic cells that suppress CD8+T cell antitumor immunityThe FASEB Journal.  22. 2008
2008 An antibiotic-responsive mouse model of fulminant ulcerative colitisPLoS Medicine.  5:0424-0439. 2008
2007 Rapid Maturation of Effector T Cells in Tumors, but Not Lymphoid Organs, during Tumor RegressionPLoS ONE.  2. 2007
2007 Tumors induce regulatory dendritic cells that suppress CD8+T cell antitumor immunityJournal of Women's Health.  16:1099-1099. 2007
2006 Phenotypic maturation of tumor-infiltrating T cells is associated with heightened intratumoral cytolytic activity and tumor regressionJournal of Immunology.  176:S272-S272. 2006
2006 Tumor-infiltrating regulatory dendritic cells suppress CD8+T cell functionJournal of Immunology.  176:S272-S273. 2006
2005 T cell-mediated delay of spontaneous mammary tumor onset: Increased efficacy with in vivo versus in vitro activationJournal of Immunology.  174:4662-4669. 2005
2004 No intrinsic deficiencies in CD8+ T cell-mediated antitumor immunity with agingJournal of Immunology.  173:835-844. 2004
2004 CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell PrecursorsJournal of Immunology.  172:4215-4224. 2004
2000 The regulation of CD95 (Fas) ligand expression in primary T cells: Induction of promoter activation in CD95LP-Luc transgenic miceJournal of Immunology.  164:4471-4480. 2000
2000 Intracellular adapter molecules.Seminars in Immunology.  12:43-54. 2000
1999 Differential regulation of the IL-12 p40 promoter and of p40 secretion by CpG DNA and lipopolysaccharideJournal of Immunology.  162:6770-6775. 1999
1998 A newly identified response element in the CD95 ligand promoter contributes to optimal inducibility in activated T lymphocytes.Journal of Immunology.  161:1078-1082. 1998
1998 Cutting edge: A newly identified response element in the CD95 ligand promoter contributes to optimal inducibility in activated T lymphocytesJournal of Immunology.  161:1078-1082. 1998
1998 Regulation of CD95 (FAS) ligand expression in activated T cells and immune privileged tissuesThe FASEB Journal.  12. 1998
1997 Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cellsJournal of Biological Chemistry.  272:31427-31434. 1997
1997 NFAT binding sites participate in regulation of the CD95 (Fas) ligand promoter in activated T cells.Arthritis and Rheumatism.  40:1743-1743. 1997
1997 Regulation of CD95 (Fas) Ligand Expression by TCR-Mediated Signaling EventsJournal of Immunology.  158:4602-4611. 1997
1993 Mycoplasma bovoculi-Augmented bovine natural killer activity 1993


Year Title Altmetric
2018 Obesity-Induced Defects in Dendritic Cell and T Cell Functions: Implications for Immunotherapeutic Efficacy in Cancer.  171-181. 2018

Education And Training

  • Doctor of Philosophy in Immunology, University of Iowa 2000
  • Preferred Title

  • Associate Professor
  • Full Name

  • Lyse Norian
  • Additional Emails